Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma

Bedewy, Ahmed M.; El-Gammal, Maha; Bedewy, Magdy; EL-Maghraby, Shereen M.

doi:10.1007/s00277-013-1775-4

Cited by 13 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGF-β1 was elevated before treatment in patient with DLBCL and dramatically decreased after treatment and correlated with advanced stages, high risk international prognostic index, bulky disease and partially or non-responded patients so it is linked to all bad prognostic factors, complete response was achieved in 42 patients (84.0%) while four patients (8.0%) had partial remission and four patients (8.0%) had no response to protocol of chemotherapy and these data were consistent with the study of Bedewy et al [20], in which 178 Egyptian patients (79.5%) achieved complete response after the R-CHOP regimen with follow-up period of 51 months.…”

Section: Tgf-β1supporting

confidence: 81%

Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma

Elhefni¹,

Alazzazi²,

Taleb³

2015

J Hematol

View full text Add to dashboard Cite

show abstract

Section: Tgf-β1supporting

confidence: 81%

Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma

Elhefni¹,

Alazzazi²,

Taleb³

2015

J Hematol

View full text Add to dashboard Cite

show abstract

“…Some reports used a value greater than 5% as the survivin-positive cut-off, whereas others have used cut-offs of 10%, 25%, 30%, or 45% [17–19, 23, 24]. For localizing survivin immunostaining, some reports have used cytoplasmic survivin positivity, whereas others have used nuclear positivity, mixed-type positivity, or an immunoreactivity scoring system [17–19, 23, 24]. Thus, these previous studies have reported highly variable percentages of survivin-positive DLBCL in the range of 39.3% to 84.9% [19].…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

et al. 2017

View full text Add to dashboard Cite

Survivin is an inhibitor of apoptosis and is upregulated by Epstein–Barr virus (EBV) latent genes. Given the frequent association of EBV with lymphoid malignancies, survivin is expected to have prognostic value in diffuse large B-cell lymphoma (DLBCL). Thus, we measured the pretreatment serum level of survivin in DLBCL patients and analyzed its association with survival outcome and EBV status, as represented by EBV-encoded RNA (EBER) in DLBCL. Pretreatment serum survivin level was measured in patients registered in a prospective cohort study (n = 210), and serum survivin-positivity was defined as any detectable level of survivin. EBV status was determined using EBER in situ hybridization, and EBER-positivity was defined as 20% of examined cells showing nuclear positivity. Mean serum survivin level was higher in patients with relapsed or refractory disease than with responsive disease (59.89 pg/mL versus 17.34 pg/mL, P = 0.041). Serum survivin-positive patients had worse overall and progression-free survival (P = 0.023 and 0.022, respectively). Serum survivin positivity was associated with unfavorable characteristics including stage. In patients with non-germinal center B-cell type DLBCL, serum survivin-positive patients also had significantly worse survival than serum survivin-negative patients (P < 0.001). EBER-positivity was found in 6.7% (14/210) of patients, and EBER-positive patients had worse survival (P < 0.05). Patients having concomitant positivity for serum survivin and EBER expression (2.8%, 6/210) showed extremely poor prognosis. In the present era of rituximab in DLBCL, DLBCL with serum survivin positivity showed adverse clinical features and followed worse clinical course, especially in non-GCB subtype DLBCL. EBER-positivity was still associated with worse outcomes in DLBCL.

show abstract

“…Survivin expression in Ewing sarcoma, another type of human bone sarcoma, has been shown to be a poor prognostic marker . Survivin expression is a negative prognostic factor in both dogs with B‐cell lymphoma and in human B‐cell lymphoma . Survivin expression has been identified in select other canine neoplasms .…”

Section: Introductionmentioning

confidence: 99%

Survivin inhibition via EZN‐3042 in canine lymphoma and osteosarcoma

Shoeneman

Ehrhart

Charles

et al. 2014

Vet Comparative Oncology

View full text Add to dashboard Cite

Canine lymphoma (LSA) and osteosarcoma (OS) have high mortality rates and remain in need of more effective therapeutic approaches. Survivin, an inhibitor of apoptosis (IAP) family member protein that inhibits apoptosis and drives cell proliferation, is commonly elevated in human and canine cancer. Survivin expression is a negative prognostic factor in dogs with LSA and OS, and canine LSA and OS cell lines express high levels of survivin. In this study, we demonstrate that survivin downregulation in canine LSA and OS cells using a clinically applicable locked nucleic acid antisense oligonucleotide (EZN-3042, Enzon Pharmaceuticals, Piscataway Township, NJ, USA) inhibits growth, induces apoptosis and enhances chemosensitivity in vitro, and inhibits survivin transcription and protein production in orthotopic canine OS xenografts. Our findings strongly suggest that survivin-directed therapies might be effective in treatment of canine LSA and OS and support evaluation of EZN-3042 in dogs with cancer.

show abstract

Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin’s lymphoma

Cited by 13 publications

References 38 publications

Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma

Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Survivin inhibition via EZN‐3042 in canine lymphoma and osteosarcoma

Contact Info

Product

Resources

About